Cited 1 times in
Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강은석 | - |
dc.contributor.author | 김영숙 | - |
dc.contributor.author | 이민영 | - |
dc.contributor.author | 이병완 | - |
dc.contributor.author | 차봉수 | - |
dc.date.accessioned | 2022-08-23T00:38:14Z | - |
dc.date.available | 2022-08-23T00:38:14Z | - |
dc.date.issued | 2022-06 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/189538 | - |
dc.description.abstract | Aims: Glucagon-like peptide 1 (GLP-1) receptor agonists have demonstrated strong glycemic control. However, few studies have investigated the effects of switching from insulin to GLP-1 receptor agonists. We aimed to investigate, using real-world data, whether switching to dulaglutide improves glycemic control in patients with type 2 diabetes mellitus (T2D) inadequately controlled with conventional insulin treatment. Materials and methods: We retrospectively evaluated 138 patients with T2D who were switched from insulin to dulaglutide therapy. We excluded 20 patients who dropped out during the follow-up period. The participants were divided into two groups according to whether they resumed insulin treatment at 6 months after switching to a GLP-1 receptor agonist (group I) or not (group II). A multiple logistic regression analysis was performed to evaluate the parameters associated with the risk of resuming insulin after replacement with dulaglutide. Results: Of 118 patients initiated on the GLP-1 receptor agonist, 62 (53%) resumed insulin treatment (group I), and 53 (47%) continued with GLP-1 receptor agonists or switched to oral anti-hypoglycemic agents (group II). Older age, a higher insulin dose, and lower postprandial glucose levels while switching to the GLP-1 receptor agonist were associated with failure to switch to the GLP-1 receptor agonist from insulin. Conclusions: A considerable proportion of patients with T2D inadequately controlled with insulin treatment successfully switched to the GLP-1 receptor agonist. Younger age, a lower dose of insulin, and a higher baseline postprandial glucose level may be significant predictors of successful switching from insulin to GLP-1 receptor agonist therapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Frontiers Research | - |
dc.relation.isPartOf | FRONTIERS IN ENDOCRINOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Blood Glucose / analysis | - |
dc.subject.MESH | Diabetes Mellitus, Type 2* / drug therapy | - |
dc.subject.MESH | Glucagon-Like Peptide-1 Receptor / agonists | - |
dc.subject.MESH | Glucagon-Like Peptides / analogs & derivatives | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunoglobulin Fc Fragments | - |
dc.subject.MESH | Insulin* | - |
dc.subject.MESH | Recombinant Fusion Proteins | - |
dc.subject.MESH | Retrospective Studies | - |
dc.title | Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Youngsook Kim | - |
dc.contributor.googleauthor | Ji Hye Huh | - |
dc.contributor.googleauthor | Minyoung Lee | - |
dc.contributor.googleauthor | Eun Seok Kang | - |
dc.contributor.googleauthor | Bong-Soo Cha | - |
dc.contributor.googleauthor | Byung-Wan Lee | - |
dc.identifier.doi | 10.3389/fendo.2022.880164 | - |
dc.contributor.localId | A00068 | - |
dc.contributor.localId | A00715 | - |
dc.contributor.localId | A05491 | - |
dc.contributor.localId | A02796 | - |
dc.contributor.localId | A03996 | - |
dc.relation.journalcode | J03412 | - |
dc.identifier.eissn | 1664-2392 | - |
dc.identifier.pmid | 35784534 | - |
dc.subject.keyword | GLP-1 receptor agonist | - |
dc.subject.keyword | insulin therapy | - |
dc.subject.keyword | switching to GLP-1 receptor agonist | - |
dc.subject.keyword | type 2 diabetes | - |
dc.subject.keyword | type 2 diabetes inadequately controlled with insulin therapy | - |
dc.contributor.alternativeName | Kang, Eun Seok | - |
dc.contributor.affiliatedAuthor | 강은석 | - |
dc.contributor.affiliatedAuthor | 김영숙 | - |
dc.contributor.affiliatedAuthor | 이민영 | - |
dc.contributor.affiliatedAuthor | 이병완 | - |
dc.contributor.affiliatedAuthor | 차봉수 | - |
dc.citation.volume | 13 | - |
dc.citation.startPage | 880164 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN ENDOCRINOLOGY, Vol.13 : 880164, 2022-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.